Seizing The Day: How Coronavirus Breaks Then Makes Vaccine Makers In China
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
You may also be interested in...
While global vaccine heavyweights Merck & Co, Sanofi and GSK are so far not faring so well to successfully develop a vaccine for COVID-19, smaller players are stepping up. That's especially true for segmented markets such as China.
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.